Literature DB >> 7515098

Induction of programmed cell death in human hematopoietic cell lines by fibronectin via its interaction with very late antigen 5.

H Sugahara1, Y Kanakura, T Furitsu, K Ishihara, K Oritani, H Ikeda, H Kitayama, J Ishikawa, K Hashimoto, Y Kanayama.   

Abstract

Extracellular matrix (ECM) molecules such as fibronectin (FN), collagens, and laminin have important roles in hematopoiesis. However, little is known about the precise mechanisms by which ECM molecules regulate proliferation of human hematopoietic progenitor cells. In this study, we have investigated the effects of ECM molecules, particularly of FN, on the proliferation of a myeloid leukemia cell line, M07E, which proliferates in response to either human granulocyte/macrophage colony-stimulating factor (GM-CSF) or stem cell factor (SCF). The [3H]thymidine incorporation and cell enumeration assays showed that FN strikingly inhibited GM-CSF- or SCF-induced proliferation of M07E cells in a dose-dependent manner, whereas little or no inhibition was induced by collagen types I and IV. The growth suppression of M07E cells was not due to the inhibitory effect of FN on ligand binding or very early events in the signal transduction pathways from the GM-CSF or SCF receptors. DNA content analysis using flow cytometry after staining with propidium iodide revealed that the treatment of M07E cells with FN did not block the entry of the cells into the cell cycle after stimulation with GM-CSF or SCF, whereas the treatment resulted in the appearance of subdiploid peak. Furthermore, FN was found to induce oligonucleosomal DNA fragmentation and chromatin condensation in the cells even in the presence of GM-CSF or SCF, suggesting the involvement of programmed cell death (apoptosis) in the FN-induced growth suppression. The growth suppression or apoptosis induced by FN was rescued by the addition of either anti-FN antibody, anti-very late antigen 5 monoclonal antibody (anti-VLA5 mAb), or GRGDSP peptide, but not by that of anti-VLA4 mAb or GRGESP peptide, suggesting that the FN effects on M07E cells were mediated through VLA5. In addition, the FN-induced apoptosis was detectable in VLA5-positive human hematopoietic cell lines other than M07E cells, but not in any of the VLA5-negative cell lines. These results suggest that FN is capable of inducing apoptosis via its interaction with VLA5, and also raise the possibility that the FN-VLA5 interaction may contribute, at least in part, to negative regulation of hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515098      PMCID: PMC2191510          DOI: 10.1084/jem.179.6.1757

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  54 in total

Review 1.  Adhesion receptors of the immune system.

Authors:  T A Springer
Journal:  Nature       Date:  1990-08-02       Impact factor: 49.962

2.  Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque.

Authors:  D English; B R Andersen
Journal:  J Immunol Methods       Date:  1974-08       Impact factor: 2.303

3.  Extracellular matrix production by the adherent cells of long-term murine bone marrow cultures.

Authors:  K S Zuckerman; M S Wicha
Journal:  Blood       Date:  1983-03       Impact factor: 22.113

Review 4.  Stromal cell associated haemopoiesis.

Authors:  T M Dexter
Journal:  J Cell Physiol Suppl       Date:  1982

5.  Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver--conditioned medium.

Authors:  K M Zsebo; J Wypych; I K McNiece; H S Lu; K A Smith; S B Karkare; R K Sachdev; V N Yuschenkoff; N C Birkett; L R Williams
Journal:  Cell       Date:  1990-10-05       Impact factor: 41.582

6.  Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins.

Authors:  Y Kanakura; B Druker; S A Cannistra; Y Furukawa; Y Torimoto; J D Griffin
Journal:  Blood       Date:  1990-08-15       Impact factor: 22.113

7.  Direct stimulation of cells expressing receptors for macrophage colony-stimulating factor (CSF-1) by a plasma membrane-bound precursor of human CSF-1.

Authors:  J Stein; G V Borzillo; C W Rettenmier
Journal:  Blood       Date:  1990-10-01       Impact factor: 22.113

8.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.

Authors:  T Furitsu; T Tsujimura; T Tono; H Ikeda; H Kitayama; U Koshimizu; H Sugahara; J H Butterfield; L K Ashman; Y Kanayama
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

9.  Mammalian reticulocytes lose adhesion to fibronectin during maturation to erythrocytes.

Authors:  V P Patel; A Ciechanover; O Platt; H F Lodish
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

10.  Control of intracellular pH and growth by fibronectin in capillary endothelial cells.

Authors:  D E Ingber; D Prusty; J V Frangioni; E J Cragoe; C Lechene; M A Schwartz
Journal:  J Cell Biol       Date:  1990-05       Impact factor: 10.539

View more
  17 in total

1.  Enhancement of activation-induced cell death by fibronectin in murine CD4+ CD8+ thymocytes.

Authors:  E Takayama; T Kina; Y Katsura; T Tadakuma
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

2.  Anti-alpha 4 integrin antibody induces apoptosis in murine thymocytes and staphylococcal enterotoxin B-activated lymph node T cells.

Authors:  E Z Tchilian; J J Owen; E J Jenkinson
Journal:  Immunology       Date:  1997-11       Impact factor: 7.397

Review 3.  The extracellular matrix of the hematopoietic microenvironment.

Authors:  G Klein
Journal:  Experientia       Date:  1995-09-29

4.  Fibronectin fragments modulate monocyte VLA-5 expression and monocyte migration.

Authors:  J Trial; R E Baughn; J N Wygant; B W McIntyre; H H Birdsall; K A Youker; A Evans; M L Entman; R D Rossen
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

5.  α2β1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK).

Authors:  Dalila Naci; Mohammed-Amine El Azreq; Nizar Chetoui; Laura Lauden; François Sigaux; Dominique Charron; Reem Al-Daccak; Fawzi Aoudjit
Journal:  J Biol Chem       Date:  2012-03-28       Impact factor: 5.157

6.  VLA-5 is expressed by mouse and human long-term repopulating hematopoietic cells and mediates adhesion to extracellular matrix protein fibronectin.

Authors:  J C van der Loo; X Xiao; D McMillin; K Hashino; I Kato; D A Williams
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

7.  Apoptotic death of hematopoietic tumor cells through potentiated and sustained adhesion to fibronectin via VLA-4.

Authors:  Yohei Saito; Toshiyuki Owaki; Takuya Matsunaga; Mizue Saze; Shogo Miura; Mao Maeda; Mayu Eguchi; Rika Tanaka; Junichi Taira; Hiroaki Kodama; Sumio Goto; Yoshiroh Niitsu; Hiroshi Terada; Fumio Fukai
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

Review 8.  The role of extracellular matrix stiffness in megakaryocyte and platelet development and function.

Authors:  Orly Leiva; Catherine Leon; Seng Kah Ng; Pierre Mangin; Christian Gachet; Katya Ravid
Journal:  Am J Hematol       Date:  2018-01-12       Impact factor: 10.047

9.  Involvement of prolonged ras activation in thrombopoietin-induced megakaryocytic differentiation of a human factor-dependent hematopoietic cell line.

Authors:  I Matsumura; K Nakajima; H Wakao; S Hattori; K Hashimoto; H Sugahara; T Kato; H Miyazaki; T Hirano; Y Kanakura
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

10.  Reappraising the role of α5 integrin and the microenvironmental support in stress erythropoiesis.

Authors:  Tatyana Ulyanova; Grigorios Georgolopoulos; Thalia Papayannopoulou
Journal:  Exp Hematol       Date:  2019-12-28       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.